Extensive Nonsegmental Pulmonary Perfusion Defects on SPECT/CT as an Early Sign of COVID-19 Infection

Ana M. Franceschi1 Robert Matthews2 Osama Ahmed2 Karen Mourtzikos3 Marika Bajc4 Dinko Franceschi2

1 Department of Radiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, New York, United States
2 Department of Radiology, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, United States
3 Department of Nuclear Medicine, John D. Dingees Veterans Affairs Hospital, Detroit, Michigan, United States
4 Department of Clinical Physiology, Lund University, Lund, Scania, Sweden

World J Nuclear Med 2022;21:210–214.

Abstract
We describe a hospitalized patient with confirmed coronavirus disease 2019 in whom the initial chest computed tomography (CT) was negative, while subsequent perfusion single-photon emission computed tomography/computed tomography imaging revealed extensive nonsegmental perfusion defects in addition to newly developing parenchymal densities. Possible reasons for these findings and their relationship to the multisystem severe acute respiratory syndrome coronavirus 2 infection are discussed in this article.

Keywords
► pulmonary embolism
► perfusion imaging
► SPECT/CT
► COVID-19
► inflammation
► pneumonia

Introduction
Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In the symptomatic patient, it is predominantly an acute respiratory disease accompanied by fever, shortness of breath, and cough, among other symptoms. The ongoing global pandemic has to date infected over 16.5 million people, resulting in approximately 655,000 deaths worldwide.1

Consequential lung inflammation, resulting in COVID-19 associated pneumonia, is usually diagnosed by characteristic changes on chest X-ray or thoracic computed tomography (CT) imaging. Typically, chest CT demonstrates nonspecific bilateral abnormalities, with ground glass opacities in milder forms progressing to widespread consolidation in more severe forms of disease.2–5 Eventually, progressive atypical respiratory system distress may develop over time, and other organ systems are frequently affected including the central nervous system, heart, and kidneys. This may be related to the propensity of SARS-CoV-2 and related viruses for the angiotensin-converting enzyme 2 receptor, which is a relatively common functional receptor in multiple organ systems.6,7 Furthermore, an important complication of COVID-19 infection is thromboembolic disease and effective, even high-dose prophylaxis is required and recommended according to clinicians treating COVID-19 patients. There is
an increasing body of evidence that blood clots are a major cause of multisystem organ dysfunction, including the respiratory failure in severe cases of SARS-CoV-2 infection.\textsuperscript{8–10}

\section*{Case Report}

A 49-year-old female with multiple comorbidities including alcoholic liver cirrhosis with sequelae of portal hypertension and poorly controlled hypothyroidism presented to the hospital with worsening diffuse abdominal pain and distension over a 2-month period. Upon arrival to the emergency room, the patient was saturating 95\% on 2 L of oxygen via nasal cannula and was afebrile. The patient’s laboratory values were notable for acute kidney injury with creatinine of 1.5 (baseline Cr 0.9). CT of the chest, abdomen, and pelvis was performed that demonstrated cirrhotic liver and massive volume of intra-abdominal ascites. Chest CT was unremarkable, but the patient was placed under investigation for COVID-19 disease given the current high prevalence in the New York region. Nasopharyngeal swab was obtained and polymerase chain reaction (PCR) for SARS-CoV-2 initially came back negative.

On day 4 of hospitalization, the patient developed some shortness of breath, and was noted to be saturating at 91\% on 2 L of oxygen via nasal cannula, which improved to 99\% on nasal cannula with oxygen flow rate of 4 to 5 L. The patient otherwise remained afebrile. D-dimer was obtained and was elevated at 1,303 ng/mL. Given the patient’s poor kidney function and negative chest CT 3 days earlier, nuclear ventilation–perfusion lung scan was requested.

Per our institutional policy and national guidelines related to the coronavirus pandemic, the ventilation portion of the lung scan was not obtained. Instead, just lung perfusion imaging was performed using planar and single photon emission tomography/computed tomography (SPECT/CT) acquisitions.

The chest CT portion of the study demonstrated new multiple bilateral, peripheral predominant, consolidative lung opacities with reticulations typical of interstitial COVID-19 pneumonia and small pleural effusions (►Fig. 1). The SPECT images revealed markedly abnormal lung perfusion with heterogeneous radiotracer distribution, including multiple large nonsegmental areas of reduced or absent perfusion with “stripe sign” in both lungs characteristic of lung inflammation, even without underlying parenchymal changes on corresponding CT images.\textsuperscript{11} In addition, multiple subsegmental perfusion defects typical for small pulmonary emboli were also observed (►Figs. 2 and 3). Total preserved lung perfusion function was estimated to be approximately one-third of normal function.

Given these findings, the patient was retested for COVID-19 and repeat PCR analysis for SARS-CoV-2 was positive.

\section*{Discussion}

Imaging is an essential aspect of management of COVID-19 patients to evaluate the extent of different organ system involvement, severity, and progression of disease. According to recent published radiology literature, the characteristic CT findings of COVID-19 associated pneumonia most commonly include bilateral, peripheral ground-glass opacities predominantly in the lower lobes accompanied by consolidation and cavitation in more severe cases.\textsuperscript{2–4} These imaging findings are nonspecific and are associated with other infectious and noninfectious inflammatory diseases.\textsuperscript{5} In the current critical review, Raptis et al argue that chest CT should not be used as a screening or diagnostic tool, but instead should be reserved for evaluation of complications of COVID-19 pneumonia or for assessment if alternative diagnoses are suspected.\textsuperscript{12} The same conclusion was summed up in recent recommendations and position statements of several national and international organizations. Furthermore, since chest CT findings

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Fig1.png}
\caption{Noncontrast chest computed tomography (CT) obtained as part of the lung perfusion single-photon emission computed tomography/computed tomography scan (\textit{left}) in the sagittal plane (\textit{left}) demonstrating multiple peripheral consolidative opacities (arrows) with air bronchograms and reticulations in the left upper lobe. These findings are characteristic of coronavirus disease 2019 pneumonia in the appropriate clinical setting. Notably, contrast-enhanced chest CT (\textit{right}) in the sagittal plane obtained 3 days prior was unremarkable, only demonstrating subsegmental plate-like atelectasis in the left lower lobe.}
\end{figure}
Fig. 2 Chest computed tomography (CT) (upper left) and single-photon emission computed tomography-computed tomography (SPECT/CT) perfusion images (upper right) in the axial plane at the mid lung level demonstrate multiple peripheral consolidative lung opacities with reticulation predominantly in the left upper lobe as well as the right upper lobe (arrowheads) with corresponding areas of decreased perfusion. A new small right-sided pleural effusion has been also developed. SPECT perfusion imaging in the axial plane (left lower) reveals multiple small peripheral perfusion defects (thin arrows) corresponding to peripheral vascular territories on CT reflecting probable small emboli. SPECT perfusion in the coronal plane (right lower) of the posterior lungs demonstrates large areas of central perfusion defects (wide arrows) not corresponding to vascular territories ("stripe sign").

Fig. 3 Single-photon emission computed tomography (SPECT) (left) and SPECT/CT perfusion images (right) in the axial plane near the lung bases demonstrate large areas of central perfusion defects (wide arrows) not reflecting vascular territories. These may represent areas of inflammation with characteristic "stripe sign" (thin arrows) and without underlying CT abnormalities.
may be normal in up to 15% of individuals with COVID-19 infection, a normal chest CT cannot exclude the disease with certainty. However, an initial chest CT is a useful method in the rapid preliminary diagnosis of SAR-CoV-2 infection so that the suspected patient may be isolated and treated in time.\textsuperscript{13,14}

Evidence has also accumulated that a subgroup of patients with severe COVID-19 disease develop cytokine storm syndrome.\textsuperscript{15,16} In these cases, hyperinflammation due to rapid accumulation of T-cells and macrophages results in release of massive level of cytokines into the bloodstream aiming to destroy the offending pathogen causing numerous manifestations starting from the atypical respiratory system distress and fever, and progressing to multiorgan system dysfunction involving the heart, kidneys, and the central nervous system.\textsuperscript{17,18} Thromboembolic disease giving rise to pulmonary embolism is an additional important complication of SARS-CoV-2 infection. There is apparently a causal relationship as severe inflammation and infection is a known precipitating factor for thromboembolism. Researchers in Ireland confirmed that the diffuse bilateral inflammation observed in COVID-19 is associated with significant pulmonary-specific vasculopathy that correlates with disease severity. The unexpectedly high prevalence of thromboembolism among affected patients and COVID-19 associated coagulopathy with elevated markers such as D-dimer and fibrinogen has been increasingly recognized in regions with high disease prevalence.\textsuperscript{19,20} A recent study from France revealed that 30% of patients with COVID-19 infection had acute pulmonary emboli on pulmonary computed tomography angiography, a striking percentage.\textsuperscript{21} Similarly, investigators from the Netherlands reported remarkably high, 31% incidence of thrombotic complications in intensive care unit patients with COVID-19 despite at least standard low-dose heparin prophylaxis.\textsuperscript{8} The first series of autopsies in the United States from New Orleans showed bilateral diffuse alveolar damage with lymphocytic infiltrate predominantly in the interstitial spaces and fibrin thrombi within the capillaries and small vessels throughout the lungs.\textsuperscript{22} Reported autopsy results from Italy indicate that in addition to diffuse inflammatory infiltrate, major relevant lung finding is the presence of platelet-fibrin thrombi in small arterial vessels that is important in the clinical context of coagulopathy dominating the clinical course in these patients.\textsuperscript{23}

While elevated D-dimer is a frequent finding in COVID-19 infection, it is not specific for the diagnosis of venous thromboembolism.\textsuperscript{15} On the other hand, CT angiography may contribute to, or even cause development of acute kidney injury in these patients already at risk of renal failure. Therefore, consideration should be given to lung perfusion radionuclide scan as the preferred imaging modality when pulmonary embolism is suspected in SARS-CoV-2 patients. Furthermore, based on the presented case we postulate that functional abnormalities evident as widespread perfusion reduction on radionuclide perfusion tomographic images may precede abnormal morphological findings on chest CT in some patients. The extent of abnormal perfusion defects likely reflects widespread lung inflammation and multiple small thromboemboli without corresponding structural damage on CT images was an unexpected finding in the presented case of patient with COVID-19 pneumonia. These findings are in accordance with the reported clinical course of disease and underlying pathological findings. This patient had multiple comorbidities and there are other possible explanations for the perfusion defects including vascular and oxygenation changes from a pulmonary manifestation of cirrhosis or portal hypertension, as well as long-term lung damage and possible autoimmune disease linked to the poorly controlled hypothyroidism. Chest CT remains an important initial imaging approach in COVID-19 patients with the addition of CT angiography when thromboembolism is suspected. Functional perfusion imaging in combination with low-dose CT (SPECT/CT) is an alternative study in COVID-19 patients when thromboembolism is suspected. In addition, SPECT/CT perfusion imaging may visualize and assess early lung parenchymal changes caused by interstitial pneumonia and related comorbidities such as pulmonary embolism, pulmonary hypertension, and heart failure.\textsuperscript{11} In institutions without a SPECT/CT camera, SPECT imaging alone may be useful especially if it can be fused with chest CT for correlation.

**Conclusion**

Comorbidity of pneumonia and pulmonary embolism is a frequent finding in COVID-19 infection. Although chest CT is the mainstay for the evaluation of these lung pathologies, hybrid SPECT/CT imaging technology can be useful as an adjunct or alternative study. Lung perfusion SPECT/CT may identify pulmonary embolism including small subsegmental emboli, as well as parenchymal lung changes on underlying chest CT images in patients with COVID-19 disease. In this case study, we showed extensive SPECT/CT nonsegmental perfusion defects that we hypothesize may indicate an early lung involvement or inflammatory changes in SARS-CoV-2 infection.

This imaging approach should be considered in the management of COVID-19 patients, and further evaluated in well-planned prospective clinical studies.

**Declaration of Patient Consent**

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patients have given their consent for the images and other clinical information to be reported in this journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Note**

The work was carried out at the Department of Radiology at Stony Brook University Hospital.

**Funding**

None.

**Conflicts of Interest**

None declared.
Nonsegmental Pulmonary Perfusion Defects COVID-19

Franceschi et al.

References

1. Coronavirus disease (COVID-19) Pandemic. Geneva: World Health Organization https://www.who.int/emergencies/diseases/novel-coronavirus-2019 Accessed April 5, 2022
2. Salehi S, Abedi A, Balakrishnan S, Gholamrezaezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. AJR Am J Roentgenol 2020;214(05):1078–1082
3. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol 2020;30(08):4381–4389
4. Simpson S, Kay FU, Abbara S, et al. Radiological Society of North America Expert Consensus document on reporting chest CT findings related to COVID-19: endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA. Radiol Cardiothorac Imaging 2020;2(02):e200152. Doi: 10.1148/ryct.2020200152
5. Bai HX, Hsieh B, Xiong Z, et al. Performance of radiologists in differentiating COVID-19 from non-COVID-19 viral pneumonia at chest CT. Radiology 2020;296(02):E46–E54. [Epub ahead of print]
6. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus, A first step in understanding SARS pathogenesis. J Pathol 2004;203(02):631–637
7. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426(6965):450–454
8. Klok FA, Kruijf MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–147
9. Wadman M, Couzi-Frankel J, Kaiser J, Matacic C. How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes. Science 2020;17:1502–1503
10. Poor HD, Ventetuolo CE, Tolbert T, et al. COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. medRxiv preprint. doi: https://doi.org/10.1101/2020.04.17.20057125
11. Bajc M, Schümichen C, Grüning T, et al. EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond. Eur J Nucl Med Mol Imaging 2019;46(12):2429–2451
12. Raptis CA, Hammer MM, Short RG, et al. Chest CT and coronavirus disease (COVID-19): a critical review of the literature to date. AJR 2020;2020:215
13. Hosseiny M, Kooraki S, Gholamrezaezhad A, Reddy S, Myers L. Radiology perspective of coronavirus disease 2019 (COVID-19): lessons from severe acute respiratory syndrome and Middle East respiratory syndrome. AJR Am J Roentgenol 2020;214(05):1078–1082
14. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology 2020; [Epub ahead of print]
15. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJHLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395(10229):1033–1034
16. Wang W, He J, Lie P, et al. The definition and risks of cytokine release syndrome-like in 11 COVID-19-infected pneumonia critically ill patients: Disease Characteristics and Retrospective Analysis [preprint, April 2020]. https://doi.org/10.1101/2020.02.26.20026989
17. Xie J, Tong Z, Guan X, Du B, Qiu H. Clinical characteristics of patients who died of coronavirus disease 2019 in China. JAMA Netw Open 2020;3(04):e205619
18. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46(05):846–848; [Epub ahead of print]. Doi: 10.1007/s00134-020-05991-x
19. Fogarty H, Townsend L, Ni Cheallaigh C, et al. COVID19 coagulopathy in Caucasian patients. Br J Haematol 2020;189(06):1044–1049
20. Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol 2020;7(05):e362–e363
21. Léonard-Lorant I, Delabranche X, Séverac F, et al. Acute pulmonary embolism in patients with COVID-19 at CT angiography and relationship to d-Dimer levels. Radiology 2020;296(03):E189–E191 [published online ahead of print, 2020 Apr 23]
22. Foulley JL, Aburto-Martín A, Refinetti A, et al. COVID-19 pulmonary and cardiac pathology in 2020. Eur J Radiol 2020;128:108269
23. Fox SE, Akmatbekov A, Harbert JL, Li G, Brown Q, Vander Heife RS. Pulmonary and cardiac pathology in Covid-19: the first autopsy series from New Orleans. medRxiv preprint (April 2020). Doi: 10.1101/2020.04.06.20050575
24. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. [preprint, April 2020]. https://doi.org/10.1101/2020.04.19.20054262